Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER's Newest "Super-Office" Focuses On Drug Security

This article was originally published in The Pink Sheet Daily

Executive Summary

Reorganization of FDA Center for Drug Evaluation and Research's Office of Compliance includes a new entity dedicated to supply chain integrity, imports and recalls.

You may also be interested in...



CDER’s Drug Integrity Program Gains Formal Role In Compliance Office Reorg

FDA’s nascent Drug Integrity and Security Program gains an enhanced and more formal role with the reorganization and elevation of the Center for Drug Evaluation and Research’s Office of Compliance to “super-office” status.

CDER’s Drug Integrity Program Gains Formal Role In Compliance Office Reorg

FDA’s nascent Drug Integrity and Security Program gains an enhanced and more formal role with the reorganization and elevation of the Center for Drug Evaluation and Research’s Office of Compliance to “super-office” status.

CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal

Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel